Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequences - Takeaways - MDSpire

Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequences

  • By

  • Maximilian Haack

  • Vanessa Miksch

  • Zhe Tian

  • Gregor Duwe

  • Anita Thomas

  • Angelika Borkowetz

  • Kristina Stroh

  • Christian Thomas

  • Axel Haferkamp

  • Thomas Höfner

  • Katharina Boehm

  • November 1, 2022

  • 0 min

Share

  • 1

    Multiparametric MRI (mpMRI) is recommended prior to prostate biopsy, but its necessity in MRI-negative patients remains debated.

  • 2

    A study analyzed outcomes of 216 men with negative mpMRI, revealing 20.7% had prostate cancer, but only 6.7% had clinically significant cancer.

  • 3

    Additional prognostic factors like PSA levels and density are used in PCa management, but their effectiveness in MRI-negative patients is unclear.

  • 4

    Older age at initial mpMRI was identified as an independent predictor for undergoing biopsy after a negative mpMRI.

  • 5

    The study highlights the need for further investigation into the management of patients with negative mpMRI and suspicion of prostate cancer.

Original Source(s)

Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequences

  • by Maximilian Haack, Vanessa Miksch, Zhe Tian, Gregor Duwe, Anita Thomas, Angelika Borkowetz, Kristina Stroh, Christian Thomas, Axel Haferkamp, Thomas Höfner, Katharina Boehm

  • November 1, 2022

Related Content

Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies

Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population

Novel contrast-enhanced ultrasound imaging in prostate cancer